As antiretroviral therapy advancements focus on long-acting medications, there is a need to assess the potential impact of drug-drug interactions. We present a real-world case of long-acting cabotegravir/rilpivirine co-administered with intravenous rifampin. The combination resulted in both cabotegravir and rilpivirine concentrations falling below 4 times the protein-adjusted IC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10745268 | PMC |
| http://dx.doi.org/10.1093/ofid/ofad604 | DOI Listing |
Publication Analysis
Top Keywords
long-acting cabotegravir/rilpivirine
8
intravenous rifampin
8
cabotegravir/rilpivirine concentrations
4
concentrations combination
4
combination intravenous
4
rifampin case
4
case report
4
report antiretroviral
4
antiretroviral therapy
4
therapy advancements
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!